Phase I trial to evaluate the safety, tolerability and pharmacokinetics of ADX 71441

Trial Profile

Phase I trial to evaluate the safety, tolerability and pharmacokinetics of ADX 71441

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Jan 2017

At a glance

  • Drugs ADX 71441 (Primary)
  • Indications Alcoholism; Charcot-Marie-Tooth disease; Smoking withdrawal
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 09 Jan 2017 According to an Addex Therapeutics media release, this trial is scheduled to start in 2017.
    • 11 Apr 2016 According to an Addex Therapeutics media release, ADX71441 received regulatory approval to start phase I and will be investigated in Charcot-Marie-Tooth Type 1A disease (CMT1A), alcohol use disorder and nicotine dependence with support from the US CMT Association, the US National Institute on Alcohol Abuse and Alcoholism, and the US National Institute on Drug Abuse, respectively.
    • 01 May 2013 Addex Therapeutics expected to initiate this trial during the H1 of 2013. The trial was planned to initially focus on evaluating ADX 71441 for the treatment of spasticity in patients with multiple sclerosis (MS). Following positive proof-of-concept data, Addex plans to move to phase IIa testing for Charcot-Marie-Tooth 1A (CMT1A) disease. Addex is developing ADX 71441 for the potential treatment of CMT1A, spasticity in patients with MS, pain, and overactive bladder.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top